Are there particular subsets of AAV patients in which avacopan is more effective?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but wondering if there are any trends/signals.
Community PollStarted
In which patients will you recommend avacopan, once approved, in the treatment of AAV?
22 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Rheumatology · Director, Vasculitis Clinical Research Consortium
Answered on
The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:
Patients in the ADVOCATE trial were stratified at entry according to time of diagnosis (new/relapsing), diagnosis (GPA/MPA), ANCA serotype (PR3/MPO), and background immunosuppressive (cyclophosphamide/rituximab) with re...
Join for free or sign in to see the full answer